Inspired by family, a new Duchenne foundation and biotech launch in Boston
While a student at Harvard Business School, Rich Horgan, 26, founded a Boston nonprofit called Terry’s Foundation for Muscular Dystrophy last year, and an affiliated for-profit biotech called Myos. Last month, he was named a Blavatnik Fellow, giving him the chance to work with Harvard inventors and Harvard-affiliated hospitals on advancing both projects.
But the impetus for the nonprofit and company was largely personal: Horgan hopes to find a treatment for his brother, Terry, 23, who has a genetic mutation that causes Duchenne muscular dystrophy. It’s a mutation that’s rare even by rare disease standards, and Rich says no one else is working on anything that could conceivably treat him.